Physician profile
Paul D Hamm
NPI 1275537862
$2,334.69
in general payments reported to CMS, 2019-2025
22 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $163 · 2021: $576 · 2022: $706 · 2023: $321 · 2024: $13.61 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $478.39 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $280.05 | 2019-2022 | |
| Lilly USA, LLC | $189.90 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $107.19 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.91 | 2019-2023 | Steglatro |
| Janssen Pharmaceuticals, INC | $83.17 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.05 | 2019-2022 | |
| Amarin Pharma, INC. | $61.85 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $58.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $57.18 | 2022-2023 | |
| Abbott Laboratories | $48.71 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $42.67 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.48 | 2023 | Xifaxan, Trulance |
| Abbvie INC. | $33.33 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2022-2023 | Eliquis |
| Amgen INC. | $27.88 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $23.78 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.63 | 2019 | |
| Alkermes, INC. | $19.72 | 2019 | |
| Boston Scientific Corporation | $18.04 | 2025 | Ams 700 |
| Glaxosmithkline, LLC. | $15.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.